- Oxford Biomedica (OXB) has acquired a commercial-scale, FDA-approved viral vector manufacturing facility in Durham, North Carolina, for $4.5 million, expanding its US CDMO capabilities.
- The site is expected to be operational by Q1 2026 and will support late-stage and commercial AAV programmes, complementing OXB’s global network while maintaining the company’s existing financial guidance.
Oxford Biomedica plc has signed and closed an asset purchase to acquire a custom-built viral vector manufacturing facility in Durham, North Carolina, from RTP Operating, LLC, a subsidiary of National Resilience Holdco, Inc. The FDA-approved site adds commercial-scale GMP capacity for drug substance and fill-finish activities, particularly supporting adeno-associated virus (AAV) programmes.
The acquisition complements OXB’s global network, which includes sites in Oxford, Lyon, Strasbourg, and Bedford, Massachusetts. The Durham site features two operational GMP drug substance suites, a dedicated fill-finish suite, an expansion-ready GMP suite, on-site QC labs, and warehousing. The Bedford, MA site will continue as an AAV centre of excellence for early-stage process and analytical development, while Durham will focus on clinical and commercial activities.
The $4.5 million (£3.4 million) transaction, funded from existing cash, is expected to deliver a single-digit gain in 2025, offsetting acquisition-related and operational costs. Key operations are planned to be functional by Q1 2026, with additional operational staff to support full commercial readiness, increased fill-finish capacity, and faster client onboarding.
“This acquisition is a major milestone in OXB’s evolution as a global, innovation-led CDMO partner of choice. The FDA-approved facility in North Carolina adds commercial-scale US manufacturing capabilities, accelerating OXB’s ability to meet growing demand from existing clients while supporting new business opportunities.”
Dr. Frank Mathias, Chief Executive Officer of OXB
The acquisition aligns with OXB’s strategic initiatives, including the £60 million equity raise in August 2025 to expand US GMP capacity, improve process quality and productivity, and strengthen its competitive position in the global viral vector market. The company expects above-market growth and EBITDA profitability from FY 2025.
